8-K: IDEAYA Biosciences Outlines Ambitious 2026 Objectives

IDEAYA Biosciences, Inc. provided a business update outlining its key corporate objectives for 2026, focusing on advancing four registrational trials and several clinical programs.

Summary

• Advancing four registrational trials, including IDE849 (DLL3 TOP1 ADC) as a monotherapy in neuroendocrine cancer and darovasertib in both pre-metastatic and metastatic uveal melanoma.
• Topline results, including progression-free survival (PFS) data, from the ongoing registrational Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in first-line (1L) HLA*A2-negative metastatic uveal melanoma (mUM) are expected in Q1 2026.
• Positive topline PFS results from OptimUM-02 are anticipated to enable a potential accelerated approval filing in the United States.
• Darovasertib is anticipated to be in three randomized, Phase 3 registrational trials across all stages of uveal melanoma by H1 2026.
• Full enrollment of 437 patients for the OptimUM-02 trial was completed as of December 2025, with overall survival (OS) data expected to support a filing for full approval in 1L HLA*A2-negative mUM.
• Full enrollment of approximately 450 patients for the OptimUM-10 (neoadjuvant) trial is targeted by H1 2027.
• The OptimUM-11 (adjuvant) trial, in collaboration with Les Laboratoires Servier (Servier), is set to initiate in Q2 2026.
• Enrollment of approximately 80 HLA*A2-positive mUM patients in the single-arm, Phase 2 OptimUM-01 trial of darovasertib in combination with crizotinib is expected to complete by Q2 2026, with data to support a potential real-world evidence submission to the U.S. FDA and/or NCCN/compendia listing.
• IDE849 (DLL3 TOP1 ADC) aims to initiate a monotherapy registrational study in the second-line/refractory setting of small cell lung cancer (SCLC) and/or neuroendocrine carcinomas (NEC) by the end of 2026.
• IDE034 (B7H3/PTK7 bispecific TOP1 ADC) is slated to initiate a Phase 1 dose escalation trial in Q1 2026.
• IDE161 (PARG) will initiate clinical combination studies with IDE849 in SCLC, NEC, and other DLL3-overexpressing solid tumors in Q2 2026.
• Updated data from the Phase 1/2 combination trial of IDE397 (MAT2A) with Trodelvy in MTAP-deleted urothelial cancer will be provided at a medical conference in 2026.
• IDE892 (PRMT5) will initiate a Phase 1 monotherapy dose escalation trial in Q1 2026 to enable a combination trial with IDE397 in MTAP-deleted non-small cell lung cancer (NSCLC) in Q2 2026.
• An investigational new drug (IND) application for a potential first-in-class program targeting CDKN2A is targeted for submission by the end of 2026.
• IDE574 (KAT6/7) will initiate a Phase 1 dose escalation trial in Q1 2026.
• The company held approximately $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, expected to fund its current operating plan into 2030.
• Darovasertib commercial readiness activities are advancing in the United States and globally with partner Servier.

Sentiment

Score: 8

Explanation: The filing outlines a robust pipeline with multiple programs advancing into or towards registrational trials, strong financial runway into 2030, and clear timelines for key data readouts and trial initiations, indicating significant operational momentum and strategic execution.

Positives

• Strong cash position of approximately $1.1 billion as of September 30, 2025, expected to fund current operating plan into 2030.
• Advancing four registrational trials, indicating significant pipeline progress towards market approval.
• Anticipated potential accelerated approval filing for darovasertib in 1L HLA*A2-negative metastatic UM based on Q1 2026 PFS data.
• Full enrollment completed for the OptimUM-02 trial (437 patients) in December 2025, moving towards overall survival data for full approval.
• Initiation of new Phase 1 trials (IDE034, IDE892, IDE574) and combination studies (IDE161, IDE892+IDE397) expanding the pipeline.
• Collaboration with Servier for darovasertib commercial readiness and the OptimUM-11 trial initiation.
• Targeting a first-in-class CDKN2A program IND submission by the end of 2026, demonstrating innovation.

Risks

• Actual results could differ from forward-looking statements due to various risks and uncertainties.
• Risks related to the potential therapeutic benefits of the company's therapeutics.
• Uncertainty regarding the timing and content of clinical program updates, regulatory updates, and clinical trial data readouts.
• Uncertainty regarding the potential and timing for an accelerated approval filing for darovasertib.
• Risks associated with the timing of darovasertib in three Phase 3 registrational trials across all stages of uveal melanoma.
• Uncertainty regarding the utilization of overall survival data to support a potential full approval filing for darovasertib.
• Risks related to the timing of initiating registrational studies and other clinical trials for the company's therapeutics.
• Uncertainty regarding the timing of patient enrollments in clinical trials.
• Risks associated with the timing of IND submissions for the company's therapeutics.
• Uncertainty regarding the extent to which existing cash, cash equivalents, and marketable securities will fund the current operating plan.

Future Outlook

IDEAYA Biosciences anticipates significant clinical progress in 2026, including topline PFS data for darovasertib in Q1 2026, which could lead to an accelerated approval filing. The company expects darovasertib to be in three Phase 3 registrational trials by H1 2026 and plans to initiate several new clinical trials and IND submissions across its oncology pipeline, with its current cash position expected to fund operations into 2030.

Management Comments

• The company is focused on advancing its pipeline, particularly darovasertib, towards registrational trials and potential approvals.
• Significant progress is expected across multiple programs, including ADCs and MTAP pathway inhibitors, throughout 2026.
• The company is well-capitalized to execute its operating plan for several years.

Industry Context

The oncology space, particularly targeted therapies like ADCs and small molecule inhibitors, remains a high-growth area with significant unmet needs. IDEAYA's focus on uveal melanoma, SCLC, and neuroendocrine cancers addresses challenging indications. The advancement of multiple registrational trials and new clinical initiations positions the company as an active player in developing novel cancer treatments, aligning with the industry's push for precision medicine and combination therapies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry comparison.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through pipeline advancement, potential accelerated approvals, and a strong financial position.
• Patients: Potential for new treatment options for challenging cancers like uveal melanoma, SCLC, and neuroendocrine cancers.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline.
• Partners (Servier): Continued collaboration and potential for commercial success with darovasertib.

Next Steps

• Presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
• Expected topline PFS data from OptimUM-02 trial in Q1 2026.
• Potential accelerated approval filing in the United States for darovasertib if OptimUM-02 PFS results are positive.
• Initiate OptimUM-11 (adjuvant) trial in Q2 2026.
• Complete enrollment of HLA*A2-positive mUM patients in OptimUM-01 by Q2 2026.
• Initiate monotherapy registrational study for IDE849 by end of 2026.
• Initiate Phase 1 dose escalation trial for IDE034 in Q1 2026.
• Initiate clinical combination studies for IDE161 in Q2 2026.
• Provide updated data for IDE397 at a medical conference in 2026.
• Initiate Phase 1 monotherapy dose escalation trial for IDE892 in Q1 2026.
• Initiate combination trial with IDE397 for IDE892 in Q2 2026.
• Submit IND application for CDKN2A program by end of 2026.
• Initiate Phase 1 dose escalation trial for IDE574 in Q1 2026.
• Continue darovasertib commercial readiness activities with Servier.

Key Dates

Recommendation

The company has outlined a clear and aggressive development plan for 2026, featuring multiple programs advancing into or towards registrational trials, particularly darovasertib with potential for accelerated approval in Q1 2026. The robust cash position of $1.1 billion, providing a runway into 2030, significantly de-risks the operational execution. This combination of strong clinical momentum and financial stability makes it a compelling investment opportunity.

Keywords

IDEAYA Biosciences, Uveal Melanoma, Darovasertib, Oncology, Clinical Trials, Biotechnology, ADC, DLL3, TOP1, SCLC, Neuroendocrine Cancer, MTAP, CDKN2A, Servier, SEC Filing, 8-K